Linezolid: a review of its properties, function, and use in critical care
- PMID: 29950810
- PMCID: PMC6014438
- DOI: 10.2147/DDDT.S164515
Linezolid: a review of its properties, function, and use in critical care
Abstract
Linezolid can be considered as the first member of the class of oxazolidinone antibiotics. The compound is a synthetic antibiotic that inhibits bacterial protein synthesis through binding to rRNA. It also inhibits the creation of the initiation complex during protein synthesis which can reduce the length of the developed peptide chains, and decrease the rate of reaction of translation elongation. Linezolid has been approved for the treatment of infections caused by vancomycin-resistant Enterococcus faecium, hospital-acquired pneumonia caused by Staphylococcus aureus, complicated skin and skin structure infections (SSSIs), uncomplicated SSSIs caused by methicillin-susceptible S. aureus or Streptococcus pyogenes, and community-acquired pneumonia caused by Streptococcus pneumoniae. Analysis of high-resolution structures of linezolid has demonstrated that it binds a deep cleft of the 50S ribosomal subunit that is surrounded by 23S rRNA nucleotides. Mutation of 23S rRNA was shown to be a linezolid resistance mechanism. Besides, mutations in specific regions of ribosomal proteins uL3 and uL4 are increasingly associated with linezolid resistance. However, these proteins are located further away from the bound drug. The methicillin-resistant S. aureus and vancomycin-resistant enterococci are considered the most common Gram-positive bacteria found in intensive care units (ICUs), and linezolid, as an antimicrobial drug, is commonly utilized to treat infected ICU patients. The drug has favorable in vitro and in vivo activity against the mentioned organisms and is considered as a useful antibiotic to treat infections in the ICU.
Keywords: MRSA; VRE; antibacterial drugs; intensive care unit; linezolid.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures


Similar articles
-
Linezolid Pharmacia Corp.Curr Opin Investig Drugs. 2000 Oct;1(2):181-7. Curr Opin Investig Drugs. 2000. PMID: 11249571 Review.
-
Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Drug Resist Updat. 2014 Apr;17(1-2):1-12. doi: 10.1016/j.drup.2014.04.002. Epub 2014 Apr 6. Drug Resist Updat. 2014. PMID: 24880801 Review.
-
Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Drugs. 2015. PMID: 25673021 Review.
-
Role of linezolid combination therapy for serious infections: review of the current evidence.Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1043-1052. doi: 10.1007/s10096-019-03801-x. Epub 2020 Jan 2. Eur J Clin Microbiol Infect Dis. 2020. PMID: 31898798 Review.
-
Tedizolid: a new oxazolidinone antimicrobial.Am J Health Syst Pharm. 2014 Apr 15;71(8):621-33. doi: 10.2146/ajhp130482. Am J Health Syst Pharm. 2014. PMID: 24688035 Review.
Cited by
-
Occurrence of Florfenicol and Linezolid Resistance and Emergence of optrA Gene in Campylobacter coli Isolates from Tunisian Avian Farms.Int J Microbiol. 2024 Aug 5;2024:1694745. doi: 10.1155/2024/1694745. eCollection 2024. Int J Microbiol. 2024. PMID: 39135629 Free PMC article.
-
Rejuvenating the Activity of Usual Antibiotics on Resistant Gram-Negative Bacteria: Recent Issues and Perspectives.Int J Mol Sci. 2023 Jan 12;24(2):1515. doi: 10.3390/ijms24021515. Int J Mol Sci. 2023. PMID: 36675027 Free PMC article. Review.
-
Successful Treatment of Vancomycin-Resistant Enterococcus species Bone and Joint Infection with Daptomycin Plus Beta Lactam Agents.Infect Chemother. 2022 Dec;54(4):797-802. doi: 10.3947/ic.2022.0106. Infect Chemother. 2022. PMID: 36596688 Free PMC article.
-
Plasmid Fusion and Recombination Events That Occurred during Conjugation of poxtA-Carrying Plasmids in Enterococci.Microbiol Spectr. 2022 Feb 23;10(1):e0150521. doi: 10.1128/spectrum.01505-21. Epub 2022 Jan 19. Microbiol Spectr. 2022. PMID: 35044200 Free PMC article.
-
Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus.Front Cell Infect Microbiol. 2023 Aug 15;13:1225341. doi: 10.3389/fcimb.2023.1225341. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37655300 Free PMC article.
References
-
- Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord. 2001;1(2):181–199. - PubMed
-
- Barbachyn MR, Toops DS, Grega KC, et al. Synthesis and antibacterial activity of new tropone-substituted phenyloxazolidinone antibacterial agents 2. Modification of the phenyl ring – the potentiating effect of fluorine substitution on in vivo activity. Bioorg Med Chem Lett. 1996;6(9):1009–1014.
-
- Zyvox [package insert] Kalamazoo, MI: Pharmacia-Upjohn; 2004.
-
- Batts DH. Linezolid-a new option for treating Gram-positive infections. Oncology. 2000;14(8 Suppl 6):23–29. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical